Patent ID: 11883429
Assignee: ENLIVEX THERAPEUTICS RDO LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of prolonging survival of a subject suffering from an immune disease, an autoimmune disease, a cytokine release syndrome (CRS), a cytokine storm, a cancer, or an inflammatory disease, comprising administering to the subject a pharmaceutical composition comprising an irradiated mononuclear-enriched, early apoptotic cell preparation, wherein said early apoptotic cells are irradiated post induction of apoptosis, and wherein said irradiated mononuclear-enriched, early apoptotic cell preparation comprises
a decreased number of non-quiescent non-apoptotic cells;
a suppressed cellular activation of any living non-apoptotic cells; or
a reduced proliferation of any living non-apoptotic cells;
or any combination thereof compared with a preparation comprising a non-irradiated cell population.